Literature DB >> 2759162

Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer.

S Rasoul-Rockenschaub1, C C Zielinski, E Kubista, N Vavra, E Pospischil, A Staffen, K Czerwenka, P Aiginger, J Spona.   

Abstract

The diagnostic value of mucin-like carcinoma-associated antigen (MCA) was compared to that of carcinoembryonic antigen (CEA) and/or CA 15.3 in patients with breast cancer. A total of 368 patients with breast cancer were studied, of whom 253 were free of metastases, whereas 94 had either skeletal or visceral metastases or diffuse metastatic disease. The diagnostic sensitivity of MCA proved to be comparable to that of CA 15.3 and superior to that of CEA in patients with metastatic breast cancer. In contrast, the specificity of MCA was superior to that of CA 15.3. Finally, the diagnostic sensitivity of each of the tested tumour markers, i.e. MCA, CEA and CA 15.3, could be improved by their combined use. We conclude that MCA, either alone or in combination with CA 15.3 and CEA, can improve the monitoring of disease progression in patients with metastatic breast cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2759162     DOI: 10.1016/0277-5379(89)90390-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

1.  Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer.

Authors:  C G Mitter; C C Zielinski
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial.

Authors:  F Kovner; O Merimsky; M Hareuveni; N Wigler; S Chaitchik
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Use of mucin like cancer associated antigen (MCA) in the management of breast cancer.

Authors:  V Laurence; M A Forbes; E H Cooper
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.